American Society of Hematology

SHERPA: Blue

People

  1. Joffe
    Joffe
  2. Seshan
    Seshan
  3. Zelenetz
    Zelenetz
  4. Batlevi
    Batlevi
  5. Dogan
    Dogan
  6. Hamilton
    Hamilton
  7. Matasar
    Matasar
  8. Noy
    Noy
  9. Owens
    Owens
  10. Palomba
    Palomba

Groups

  1. Biostatistics Service (8)
  2. Center for Pancreatic Cancer Research (8)
  3. Department of Medicine (8)
  4. Epidemiology and Biostatistics (8)
  5. Hematologic Malignancies, Division of (8)
  6. Sloan Kettering Institute Postdocs (8)
  7. Center for Hematologic Malignancies (7)
  8. Executive Committee, Center for Hematologic Malignancies (7)
  9. Lymphoma (7)
  10. Survivorship Research (7)
Search Within
  1. "Center for Pancreatic Cancer Research"
  2. "Erel Joffe"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (2)
Groups
  1. Biostatistics Service (8)
  2. Center for Pancreatic Cancer Research (8)
  3. Department of Medicine (8)
  4. Epidemiology and Biostatistics (8)
  5. Hematologic Malignancies, Division of (8)
  6. Sloan Kettering Institute Postdocs (8)

More Groups

People
  1. Erel Joffe (8)
  2. Venkatraman Seshan (8)
  3. Andrew Zelenetz (7)
  4. Ahmet Dogan (6)
  5. Anas Younes (6)
  6. Ariela Noy (6)

More People

Years
  1. 2022 (1)
  2. 2021 (3)
  3. 2020 (3)
  4. 2019 (1)
Publications
  1. Blood (7)
  2. Blood Advances (1)

Results (8)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genetic Alterations of CREBBP are associated with radiosensitivity in follicular lymphoma
    Meeting Abstract

    Wijetunga, N. A.; Lebow, E. S.; Lee, J.; Fregonese, B.; Tringale, K. R.; Hubbeling, H.; Sarkar, R.; Ma, J.; Seshan, V.; Joffe, E.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax in chronic lymphocytic leukemia: Early MRD kinetics define a high-risk patient cohort with delayed bone marrow undetectable MRD and earlier post-treatment MRD recurrence
    Meeting Abstract

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E. P.; Barnes, J. A.; Hamilton, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era
    Journal Article

    Bobillo, S.; Joffe, E.; Lavery, J. A.; Sermer, D.; Ghione, P.; Noy, A.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • R-CHOP versus R-Bendamustine with or without rituximab maintenance in newly diagnosed follicular lymphoma patients with high SUV at baseline PET
    Meeting Abstract

    Mondello, P.; Strati, P.; Merryman, R. W.; Joffe, E.; Ruella, M.; Seshan, V.; St Pierre, F.; Major, A.; Pophali, P.; Fiasconaro, M.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Interim analysis from a prospective multicenter study of next-generation sequencing minimal residual disease assessment and CT monitoring for surveillance after frontline treatment in diffuse large B-cell lymphoma
    Meeting Abstract

    Kumar, A.; Westin, J.; Schuster, S. J.; Nowakowski, G. S.; Lossos, I. S.; Batlevi, C. L.; Caron, P.; Drullinsky, P.; Gerecitano, J.; Hamilton, A.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma
    Journal Article

    Sermer, D.; Bobillo, S.; Dogan, A.; Zhang, Y.; Seshan, V.; Lavery, J. A.; Batlevi, C.; Caron, P.; Hamilton, A.; Hamlin, P.; more...
    Blood Advances (2020)

    Fulltext@MSK | Save
  • Central nervous system prophylaxis with high-dose intravenous methotrexate or intrathecal chemotherapy in patients with diffuse large B-cell lymphoma and high-risk of CNS relapse treated in the rituximab era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Seshan, V.; Noy, A.; Horwitz, S. M.; Palomba, M. L.; Matasar, M. J.; Straus, D. J.; Hamlin, P. A.; Batlevi, C. L.; more...
    Blood (2019)

    Fulltext@MSK | Save